Home > Journals > Panminerva Medica > Past Issues > Articles online first > Panminerva Medica 2016 Sep 15


A Journal on Internal Medicine

Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6



Panminerva Medica 2016 Sep 15

language: English

Angiotensin receptor blockers and breast cancer risk: a meta-analysis

Yun F. QIAN, Wei G. XU, Jun WU

Department of Geriatrics, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, Guangdong, China


INTRODUCTION: Some studies reported that Angiotensin receptor blockers (ARBs) reduced the risk of breast cancer. However, other studies did not show similar results.
EVIDENCE ACQUISITION: The Pubmed and Embase databases were searched. The strength of the association between ARBs and the risk of breast cancer was measured by odds ratio (OR) and 95% confidence interval (CI).
EVIDENCE SYNTHESIS: Eight eligible literatures with 1994880 individuals were enrolled in this meta-analysis. ARBs was not associated with the risk of breast cancer (OR=0.93; 95%CI, 0.81–1.06; I2=86%). In the subgroup analysis of race, a significantly decreased breast cancer risk were observed in Asians (OR=0.62; 95%CI, 0.53–0.73; I2=0%). However, a significantly increased breast cancer risk were observed in Caucasians (OR=1.08; 95%CI, 1.02–1.13; I2=28%).
CONCLUSIONS: This study provided evidence that ARBs was associated with decreased breast cancer in Asians and increased risk of breast cancer in Caucasians.

top of page